Takeda Pharmaceuticals America, Inc. (TPA) and Affymax, Inc. have entered into a supply agreement for sourcing and supply of Omontys (peginesatide) Injection with DSI Renal, one of the largest dialysis providers in the U.S. Omontys is the only once-monthly erythropoiesis-stimulating agent (ESA) for anemia in adult dialysis patients with chronic kidney disease (CKD) in the U.S.   The agreement allows DSI Renal to purchase Omontys for use within its organization and provides for discounts and reba...